

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

HCG charts next phase of growth with expansion, innovation, and patient-centric cancer care

15 April 2026 | News

With plans to invest approximately Rs 200-250 crore annually in expansion



Marking 35 years of dedicated service in oncology, Healthcare Global Enterprises (HCG) has outlined an ambitious roadmap focused on expanding access, advancing clinical excellence, and leveraging cutting-edge technology to transform cancer care across India.

Building on its legacy as a single-specialty cancer care provider, HCG is entering a new phase of growth aimed at addressing the country's rapidly rising cancer burden. The organisation plans to significantly expand its infrastructure over the next four to five years by increasing its bed capacity from 2,500 to approximately 3,500 beds through a mix of brownfield expansions at existing hospitals and greenfield developments in high-need cities.

HCG has identified 10–12 emerging cities, including key tier-2 and tier-3 markets, where access to high-quality cancer care remains limited. New cancer-focused hospitals in these regions will aim to bridge critical gaps in accessibility while maintaining the organization's standards of clinical excellence.

In parallel, HCG is making substantial investments in advanced medical technologies to strengthen its precision oncology capabilities. Upcoming initiatives include the introduction of next-generation radiation therapies such as MRI-guided linear accelerators (MRI Linac), along with the continued adoption of robotic surgery systems and advanced pharmaceutical therapies, including immunotherapy.

The organisation is also prioritising digital transformation and data-driven care. Investments in artificial intelligence and analytics, integrated with its diagnostic platforms, are expected to enhance early detection, improve treatment outcomes, and enable more personalized care pathways for patients.

From a financial perspective, HCG remains committed to balancing growth with profitability. The company plans to invest approximately Rs 200–250 crore annually in expansion while maintaining steady margin improvement through operational efficiencies and optimized resource utilization.

Commenting on the future roadmap, Dr Manish Mattoo, Executive Director and CEO, HCG, said, "As cancer incidence continues to rise in India, our responsibility is not only to expand capacity but to ensure that high-quality, affordable care reaches patients across every part of the country. Our focus is on building a robust, future-ready oncology ecosystem driven by clinical excellence, cutting-edge technology, and data-led insights, while maintaining a strong commitment to patient-centric care. The next phase of our growth will be defined by scale, precision, and improved outcomes for every patient we serve."

As cancer incidence continues to rise in India, HCG aims to play a pivotal role in shaping the future of oncology care by delivering high-quality, accessible, and patient-centric treatment across the country.